Razene

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Razene

What is Razene? Defining the Medicinal Entity

Property Description
Active ingredient Cetirizine Hydrochloride (INN)
Form Tablet, Oral Solution
Pharmacological class Second-generation Antihistamine
Common use Systemic Allergy Relief
Origin Synthetic Compound

Razene: Defining the Active Substance and Classification

Razene is a medicinal product whose therapeutic effect is delivered by the single, synthetic active ingredient, Cetirizine Hydrochloride. This substance is formally classified as a second-generation antihistamine, belonging to the piperazine derivative chemical group.

The core identity of this product lies in its active compound, which carries the International Non-proprietary Name (INN) of Cetirizine Hydrochloride. Its classification as an antihistamine establishes its primary, overarching function: to oppose the effects of histamine in the body. The drug is synthesized as a single-ingredient product focused on providing relief from systemic allergic conditions and is clinically recognized for its efficacy in this regard. Cetirizine Hydrochloride acts as an H₁-receptor blocker.

Composition and Physical Forms of Cetirizine Hydrochloride

The active constituent, Cetirizine Hydrochloride, is available for oral administration in multiple high-level dosage form(s), primarily as a tablet and an oral solution.

As a synthetic compound, the active ingredient is combined with appropriate non-active materials, such as solid excipients for the tablet form or an aqueous solution base for the liquid preparation. These forms ensure effective systemic delivery of the Cetirizine Hydrochloride into the body. The compound is noted for its water solubility. Cetirizine Hydrochloride is typically marketed as a formulation intended for both the adult and pediatric population, often with the oral solution variant specifically designed to be suitable for children.

How Razene's Targeted Action Relates to Allergy Relief

The drug's primary action is achieved through highly selective H₁-receptor antagonism, functioning as a specific chemical histamine blockade that prevents the body's overreaction to allergens.

This mechanism exhibits peripheral selectivity due to its second-generation status. By concentrating its effect on H₁-receptors in body tissues outside the brain, the mechanism directly addresses the allergy symptoms driven by the release of histamine. This principle links directly to the drug's fundamental purpose: managing the disruptive physiological response to promote general allergy relief in common scenarios, such as seasonal allergic reactions.

Regulatory References

  1. Cetirizine Monograph - StatPearls - NIH
  2. NIH, Drugs and Lactation Database
  3. FDA Label

What side effects are possible with Razene?

Possible Side Effects and Safety Information

Razene (cetirizine hydrochloride) has a documented safety profile, with adverse reactions generally categorized by frequency as observed in regulatory filings and post-marketing surveillance. The drug's safety information is structured around common and serious effects, as well as specific usage restrictions.


Adverse Reaction Scope

Frequency Classification (Regulatory Sources) Adverse Reactions (Examples)
Common (≥1/100 to <1/10) Drowsiness (somnolence), fatigue, headache, dizziness, dry mouth, nausea.
Uncommon (≥1/1000 to <1/100) Agitation, abdominal pain, diarrhea, pruritus (itching), rash.
Rare (<1/1000) Convulsions, tachycardia, edema, abnormal hepatic function (usually reversible upon discontinuation), hypersensitivity reactions, aggression, confusion, depression.
Very Rare (<1/10000) Anaphylactic shock, angioedema (swelling of face/throat), thrombocytopenia, tremor, tics, blurred vision, urinary difficulty.
Not Known Rebound pruritus (severe itching after discontinuation of long-term use), urinary retention.

Safety Considerations and Restrictions

Serious Adverse Reactions: Serious and clinically significant events documented in regulatory sources include anaphylactic shock and angioedema, which represent rare but severe hypersensitivity reactions. Rare cases of convulsions and reversible hepatic dysfunction have also been noted.

Dose and Discontinuation Patterns: A specific risk involves rebound pruritus (intense itching) reported in some patients upon stopping the drug, particularly after daily use for several months or years.

Safety Restrictions:

  • Contraindications: The drug is contraindicated in patients with known hypersensitivity to cetirizine, hydroxyzine, or those with end-stage renal disease.
  • Cautionary Use: Caution is required in patients with predisposing factors for urinary retention and in epileptic patients or those at risk of convulsions. Concomitant use with alcohol is advised with caution due to the potential for increased central nervous system effects such as drowsiness.

Overdose and Emergency Response

Documented Overdose Manifestations

Official regulatory information for Razene (Cetirizine Hydrochloride) overdose describes a range of documented clinical manifestations affecting multiple physiological systems. The Central Nervous System (CNS) is commonly affected, with reported signs including somnolence (drowsiness), restlessness, irritability, confusion, stupor, and tremor. Systemic effects noted in official labeling include tachycardia (fast heart rate), pruritus, mydriasis (dilated pupils), and gastrointestinal symptoms such as diarrhea.

Required Emergency Actions and Management

Over-ingestion, particularly massive doses, is associated with a risk of severe outcomes, including seizures, coma, and urinary retention. Due to these potential life-threatening manifestations, regulators mandate that immediate medical attention be sought. Individuals must contact a Poison Control Center or Emergency Services right away.

The official product profile explicitly states that no specific antidote is known for Cetirizine. Therefore, treatment is strictly defined as symptomatic and supportive care. Procedural steps like the use of activated charcoal or gastric lavage may be considered. Hospital monitoring is often required, and continuous cardiac monitoring may be necessary in cases of massive ingestion.

In pediatric patients, regulatory documents have noted an unusual biphasic presentation of initial restlessness and irritability, followed by subsequent drowsiness and sedation.

Therapeutic Uses of Razene

Main Uses of Razene

Razene is a non-sedating antihistamine used to manage symptoms associated with allergic reactions. It is primarily utilized for the relief of conditions triggered by environmental and seasonal allergens.

Seasonal and Perennial Allergic Rhinitis

Razene is commonly used to treat symptoms of allergic rhinitis, which include:

  • Sneezing: Reducing the frequency and intensity of sneezing fits.
  • Rhinorrhea: Managing a runny nose and excess mucus production.
  • Nasal Pruritus: Relieving itchiness inside the nose.
  • Ocular Symptoms: Alleviating red, itchy, and watery eyes associated with hay fever or indoor allergens like dust mites and pet dander.

Chronic Idiopathic Urticaria

This medication is also used for the treatment of chronic idiopathic urticaria, a skin condition characterized by the recurrent appearance of hives. Razene helps to:

  • Reduce Wheals: Decrease the number and size of hives on the skin.
  • Relieve Pruritus: Significantly lessen the itching sensation associated with chronic skin allergies.

Benefits and Mechanism

Targeted Action

Razene works by blocking the H1 receptors in the body. This action prevents histamine—a chemical released during an allergic response—from binding to its receptors, thereby stopping the allergic symptoms at their source.

Non-Sedating Properties

A key benefit of Razene is its limited ability to cross the blood-brain barrier. Compared to first-generation antihistamines, it is less likely to cause drowsiness or impair mental alertness, allowing individuals to maintain their daily activities while managing allergy symptoms.

Rapid Onset

The medication is absorbed efficiently, typically providing relief from symptoms shortly after administration and maintaining its effects for a full day.

Eligibility and Restrictions for Use

Who Can and Cannot Use Razene?

This information reflects the official eligibility profile for Razene (cetirizine hydrochloride) as defined in regulatory documents and is not a substitute for professional medical advice.


Contraindicated Populations

Razene must not be used by individuals with:

  • A known history of hypersensitivity to cetirizine, to any ingredient in the formulation, to the related antihistamine hydroxyzine, or to any piperazine derivatives.
  • End-stage renal impairment (creatinine clearance less than 10 mL/min).

Age and Physiological Restrictions

Population Eligibility Status
Children under 2 years of age Use not recommended; must consult a health professional.
Children 2 to 6 years of age Must consult a health professional.
Adults 65 years and over Use may require a reduced dose; consult a health professional.
Pregnant or Breastfeeding Women Must consult a health professional; use is not recommended during breastfeeding.

Conditional Use Requirements

Use is restricted and requires consultation with a health professional for patients with non-end-stage renal impairment or hepatic impairment, as a lower, adjusted dose is necessary. Caution is advised for patients with risk factors for urinary retention (such as prostatic hyperplasia) and those with epilepsy or a risk of convulsions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Razene (Cetirizine Hydrochloride) is officially documented by regulatory authorities, focusing on additive pharmacodynamic effects and specific pharmacokinetic changes to drug clearance.

Pharmacodynamic and Substance Interactions

Co-administration with alcohol (ethanol) or other CNS depressants, such as sedatives or tranquilizers, may result in an additive CNS depressant effect. This interaction is officially noted as potentially causing additional reductions in alertness and impairment of performance in sensitive patients. Regarding food, administration with a meal decreases the rate of absorption but does not reduce the overall extent of the drug absorbed, meaning no mandatory timing separation is required.

Pharmacokinetic Exposure Changes

Specific drug-drug interactions documented in regulatory labels relate to changes in cetirizine clearance. Co-administration with Theophylline (400 mg once daily) results in a minor pharmacokinetic interaction that causes a small decrease (16%) in cetirizine clearance, which may lead to increased systemic exposure. Conversely, studies with strong enzyme inhibitors like ketoconazole or erythromycin showed no clinically significant pharmacokinetic interactions.

Population-Specific Clearance Considerations

The official profile notes that physiological conditions such as Renal Impairment and Hepatic Impairment affect drug disposition. These conditions result in decreased cetirizine clearance and a prolonged half-life, which can increase systemic exposure in these patient populations.

Mechanism of Action

Razene acts as a highly selective antagonist of the peripheral histamine H1 receptor. This biological target is primarily located on the surface of endothelial cells, respiratory smooth muscle cells, and various immune cells. By binding to the H1 receptor, Razene competitively inhibits the action of endogenous histamine, a compound released from mast cells and basophils. This inhibition prevents the histamine-mediated activation of intracellular signaling cascades, which normally include the stimulation of phosphoinositide hydrolysis and subsequent calcium mobilization. The downstream consequence of H1 receptor blockade on vascular endothelial cells is a reduction in increased vascular permeability. On the systemic level, this action modulates the local accumulation of interstitial fluid. Furthermore, Razene demonstrates secondary, H1-independent activity, which includes the suppression of inflammatory cell migration, specifically reducing the chemotaxis of eosinophils and neutrophils, thereby modulating localized tissue inflammatory responses.

Dosage and Administration Information

Razene (Cetirizine Hydrochloride) is predominantly used via the oral route, available in both a tablet and an oral solution dosage form. The administration follows a standardized principle of once-daily use for systemic effect across adult and adolescent populations. The maximum dose is 10 mg per 24 hours. The medicine's administration protocol permits dosing without regard to meals.

A key usage principle involves dose adjustments for patients with impaired renal function, where the daily dose must be reduced based on creatinine clearance; the adult dose is typically lowered to 5 mg once daily in moderate impairment. For pediatric use (children 2 to 11 years), dosing is age- and weight-dependent, and the regimen may utilize a divided twice-daily schedule in specific age brackets. The oral solution form requires measurement with a calibrated device for accuracy. Furthermore, a double dose must not be taken to compensate for a missed dose. These usage parameters define the standardized protocol for administering Cetirizine Hydrochloride.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Razene

The clinical evaluation of Razene (Cetirizine Hydrochloride) is based on evidence from controlled clinical trials and systematic reviews exploring its use in conditions related to allergic inflammation. The research focuses on describing the observed patterns of symptom changes and measuring functional outcomes across defined populations. This overview summarizes the structure of the evidence without providing clinical advice or treatment recommendations.


Evidence for Use in Seasonal and Perennial Allergic Rhinitis (SAR/PAR)

The core evidence supporting the study of Cetirizine Hydrochloride in allergic rhinitis comes from short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies are conducted during periods of increased symptom activity and often compare the compound against a placebo or other active allergy medications. These research settings are applied in studies examining patient-reported experiences related to allergic conditions characterized by fluctuating or episodic manifestations, such as hay fever (seasonal) and year-round allergies (perennial).

Research explored outcomes related to physical discomfort, focusing on the changes measured in symptom scores. These scores track the intensity or variability of symptoms like sneezing, itchy nose, runny nose, and itchy, watery eyes. While the research reports observations regarding short-term symptom patterns, the follow-up durations were often limited.

Research on Symptom Relief and Functional Outcomes

The research examined changes measured during the study period by focusing on symptoms and patient function. Findings describe patterns observed in the studies that monitored the intensity of core rhinitis symptoms. The evidence contributes to understanding symptom patterns, particularly by monitoring outcomes linked to inflammatory or irritative states. Research also monitored how patient-reported outcomes describing perceived discomfort evolved during the trials.


Evidence for Use in Chronic Idiopathic Urticaria (CIU/Hives)

Cetirizine Hydrochloride was studied for conditions characterized by fluctuating or episodic manifestations of hives, or chronic idiopathic urticaria. The evidence base includes short-term RCTs and systematic reviews. These studies primarily focused on outcomes related to physical discomfort, such as the severity and number of weals (hives), and the intensity of generalized pruritus (itching). Researchers also examined how this compound was associated with changes in patient-reported outcomes describing perceived discomfort and functional limitations.

Findings describe patterns observed in the studies where changes were measured in both the objective counting of weals and the subjective scoring of itching severity across the study groups. However, research is ongoing regarding the use of doses higher than standard for patients whose symptoms did not respond well. Studies conducted in this area often have limited follow-up durations and modest sample sizes.


Long-Term Studies and Follow-up Duration

There is limited information for long-term outcomes that would describe effects over periods exceeding several months or a year. Therefore, while research provides context, long-term outcomes related to fluctuating or unstable symptoms are not fully established.

Key Studies & References

  1. Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis
  2. Cetirizine in Children with Coexisting Allergic Rhinitis and Asthma: A Randomized Trial

Frequently Asked Questions (FAQ)

Common questions about Razene (FAQ)

Q: What's the difference between Razene and cetirizine?

A: Razene is the brand name used for this medicinal product. The active ingredient, which provides the therapeutic effect, is Cetirizine Hydrochloride. According to official product information, both the brand name and generic versions contain the same active medicinal substance.

Q: Is it normal to feel a little sleepy after taking Razene?

A: Drowsiness (somnolence) and fatigue are listed in regulatory documents as very common adverse reactions, meaning they are frequently observed side effects. Although Razene is a second-generation antihistamine, some people may still experience these effects.

Q: Does Razene interact with medications for high blood pressure?

A: Regulatory documents primarily focus on the warnings related to alcohol and other central nervous system (CNS) depressants, such as sedatives. Specific interactions with common high blood pressure medications are not explicitly highlighted in the key drug interaction information.

Q: Are there generic versions of Razene available?

A: Yes, the active ingredient, Cetirizine Hydrochloride, is widely available in generic forms from various manufacturers. These generic medications contain the same active ingredient and are required to meet the same quality and manufacturing standards as the brand-name product.

Q: Can Razene be crushed or split if someone has trouble swallowing pills?

A: Official administration instructions for some tablet formulations advise that tablets should not be divided, chewed, or crushed. The oral solution dosage form is also available, which may be suitable for those who have trouble swallowing tablets.

Q: Can Razene cause changes in appetite or weight?

A: Regulatory data indicates that increased appetite and weight gain have been reported as very rare side effects. These observations typically come from post-marketing surveillance reports.

Q: Does Razene have any known interactions with birth control pills?

A: Official information generally indicates that the active ingredient, cetirizine, is not typically expected to affect the effectiveness of hormonal contraceptives, such as birth control pills.

Q: What's the maximum number of days Razene is typically recommended for continuous use?

A: The duration of treatment is often dependent on the type, course, and severity of the condition being treated. While clinical trials often focus on short-term efficacy, long-term use is typically reserved for chronic conditions and is subject to professional review.

Q: Why do people sometimes say Razene is 'more modern' than older antihistamines?

A: Razene is classified as a second-generation antihistamine. Regulatory rationale highlights that its highly selective action primarily affects H1-receptors outside the brain. This is a property that differentiates it from first-generation antihistamines.

Q: Does Razene have any warnings about sun sensitivity?

A: Regulatory warnings and official product information typically do not list photosensitivity (increased sun sensitivity) as a common or known side effect associated with the use of cetirizine.

Q: Are there specific instructions for taking Razene if I have asthma?

A: Razene is not approved or indicated for the acute treatment of asthma. Its labeled uses are strictly for allergic conditions like rhinitis and hives. Any use by patients with asthma should be discussed with a health professional.

Q: Is Razene ever used for non-allergic conditions?

A: Regulatory approval is limited to the relief of symptoms associated with allergic rhinitis and chronic idiopathic urticaria (hives).

Q: How is Razene processed and eliminated from the body?

A: Official pharmacological data shows that Razene is primarily eliminated unchanged from the body through the kidneys (renal excretion). Only a small amount undergoes metabolism in the liver.

Q: Are there special considerations for people who are planning to become pregnant and take Razene?

A: The use of Razene is generally not recommended during pregnancy unless deemed necessary by a health professional.

Q: What is the role of Razene in a long-term allergy treatment plan?

A: Official reviews suggest that second-generation antihistamines like cetirizine are frequently recommended in clinical practice guidelines for the maintenance therapy needed for the long-term control of chronic allergic conditions.

Q: Does Razene interact with common pain relievers like ibuprofen?

A: Formal clinical studies referenced in regulatory labels have not shown adverse clinical interactions between Razene and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.

Q: What kinds of beverages should be avoided when taking Razene?

A: Official product information notes that the use of alcohol concomitantly with Razene is generally not advised. This is because combining the two may result in an additive central nervous system depressant effect, potentially increasing drowsiness or impairment.

Q: Are there any long-term side effects reported from taking Razene?

A: A specific risk of rebound pruritus (intense itching) has been reported in post-marketing surveillance upon discontinuation of the drug after long-term daily use (several months or years).

Q: Can children take Razene, and what is the typical minimum age?

A: Use of Razene is not recommended for children under 2 years of age. Regulatory labeling permits use in children as young as 2 years old with appropriate professional guidance.

Q: Has Razene been studied in people with kidney problems?

A: Yes, official pharmacological data confirms that the drug's elimination has been studied in this population. It is known that renal impairment causes a decreased clearance of the drug, and a dose adjustment is typically required in this population.

Q: What happens if I stop taking Razene suddenly?

A: Stopping the drug, particularly after use for a long period of time, has been associated with reports of rebound pruritus (intense itching) in some individuals.

Q: Why might Razene stop working after a while for some people?

A: Regulatory overviews note that research is ongoing for patients who may not respond adequately to the standard dosage over time. This indicates that individual patient responses to the medication can vary.

Q: What are the less common, but noted, side effects of Razene?

A: Less common adverse reactions listed in regulatory documents include agitation, abdominal pain, diarrhea, pruritus, and rash. These are categorized as uncommon or rare in frequency.

Q: Is Razene generally safe for people with liver conditions?

A: Caution is advised for patients with hepatic impairment (liver problems) because official information states the drug's clearance is decreased in this population. A dose adjustment is typically required in this patient population due to decreased clearance.

Q: Is it true that Razene has a lower risk of causing heart rhythm changes?

A: Regulatory data indicates that Razene is generally not associated with clinically relevant ECG changes or effects on heart rhythm at approved doses.

Q: What kind of studies were done to get Razene approved?

A: The evidence base for regulatory approval is primarily derived from short-term Randomized Controlled Trials (RCTs). These studies compared the drug's effect against placebo or other active treatments for conditions like allergic rhinitis and chronic hives.

How should Razene be stored and disposed of?

How to Store and Dispose of Razene?

The official storage and disposal requirements for Razene (cetirizine hydrochloride) are strictly defined by regulatory labeling to maintain product stability and safety.


Storage Requirements

  • Temperature and Environment: The medication must be stored at Controlled Room Temperature, specifically 20 to 25C (68 to 77F). It is required to avoid high humidity and excessive heat.
  • Light Protection: The oral solution dosage form must be specifically protected from light.
  • Packaging: Razene must be kept in its original container, and the product must not be used if the packaging seal, pouch, or blister unit is damaged or broken.
  • Child Safety: The medication must always be kept out of the reach of children.

Disposal Instructions

Expired or unused product must be handled as pharmaceutical waste. Disposal must be conducted in accordance with local requirements, which typically involves returning the medicine to a pharmacist or an approved collection point for proper discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Razene found in:

A-Z Index: